Endocrinology

Treatment Strategies: Managing FH-I

At a Glance

Familial hyperaldosteronism type I is usually treated with the lowest effective steroid dose to reduce the hormone signal that drives excess aldosterone and control blood pressure. Other medicines may be added, but potassium, kidney function, growth, and steroid effects need regular monitoring.

The primary goal of treating Familial Hyperaldosteronism Type I (FH-I) is to suppress the ACTH signal that is driving the abnormal production of aldosterone ^[1]. Because the chimeric gene is inappropriately controlled by ACTH (the hormone your brain releases to manage stress and daily rhythms), the mechanism-directed treatment is using low doses of glucocorticoids ^[1]^[2].

By taking a carefully calibrated dose of a glucocorticoid like dexamethasone or prednisone, your body signals the brain that it has enough steroids ^[2]^[3]. This causes the brain to reduce ACTH secretion, which in turn reduces the abnormal production of aldosterone ^[3].

The Balancing Act: Dosing and Harms

Because FH-I is extremely rare, there is no single “one-size-fits-all” dose. Instead, doctors follow the principle of finding the lowest effective dose to control blood pressure ^[4]. Finding this balance is crucial because over-treatment with steroids, even at low doses over a long period, can cause serious side effects:

Stunted Growth: In children, excessive glucocorticoids can slow down or stop natural growth velocity ^[5].
Cushingoid Features: This includes physical changes like rapid weight gain (especially centrally), a rounded face, and purple stretch marks (striae) ^[5]^[6].
Bone and Metabolic Health: Long-term use can lead to thinning bones (osteoporosis), insulin resistance, elevated blood sugar (glucose), and increased infection risk ^[7]^[6].
Mood and Ocular Effects: Steroids can cause mood swings or irritability, and long-term use requires monitoring for cataracts or glaucoma.
Adrenal Suppression: The body may stop producing its own natural cortisol. Never abruptly stop taking glucocorticoids without medical advice, as this can lead to a life-threatening adrenal crisis ^[8]^[9].

Because of these risks, your care team will closely monitor height, weight, mood, and metabolic markers to ensure the dose remains optimal ^[5].

Alternative and Add-on Treatments

For some patients, steroids may not fully control blood pressure, or the side effects might be too difficult to manage ^[10]. In these cases, doctors may use other medications that block aldosterone’s effects directly or help manage the hypertension:

Mineralocorticoid Receptor Antagonists (MRAs): Drugs like spironolactone or eplerenone block aldosterone from binding to its receptors, preventing it from raising blood pressure ^[11]^[12].
Amiloride: A specialized diuretic that helps the kidneys remove salt ^[13]. While small studies have shown effectiveness, dosing is highly individualized based on weight and renal function ^[14].
Calcium-Channel Blockers: These may be added to help relax blood vessels ^[2].

Important Safety Note: Both MRAs and amiloride carry a significant risk of causing high potassium (hyperkalemia) and can impact kidney function. They require strict, routine monitoring of baseline and follow-up potassium levels and kidney function tests (creatinine/eGFR). Never start, stop, or substitute these medicines without explicit instructions from your clinician.

Is Surgery an Option?

For the vast majority of people with FH-I, surgery is not appropriate because the genetic fusion is present in every cell of both adrenal glands ^[15]. However, in exceedingly rare cases, a patient with FH-I might also develop a separate, non-genetic growth (an adenoma) with secondary mutations on one of their adrenal glands ^[16]. In these rare, resistant cases, a surgeon may remove that one gland (unilateral adrenalectomy) ^[16]^[17].

Because FH-I management is complex, treatment decisions should be tailored to each patient’s specific needs by an experienced specialist, often requiring adjustments as you or your child grow and age ^[18]^[11].

Common questions in this guide

What is the usual treatment for familial hyperaldosteronism type I?

Treatment usually starts with a carefully adjusted low dose of a glucocorticoid, such as dexamethasone or prednisone. These medicines reduce ACTH, the hormone signal that drives excess aldosterone, helping control blood pressure. Other blood pressure medicines may be added if needed.

Why are steroids used to treat FH-I?

In FH-I, a genetic change makes the adrenal glands produce aldosterone in response to ACTH instead of the usual control signals. A glucocorticoid reduces ACTH release, which can lower abnormal aldosterone production. The dose is kept as low as possible to limit long-term steroid effects.

What side effects can happen with FH-I steroid treatment?

Too much or prolonged glucocorticoid treatment can slow a child's growth and cause weight gain, a rounded face, stretch marks, mood changes, high blood sugar, weaker bones, eye problems, or more infections. The care team may monitor growth, weight, mood, blood sugar, bone health, and eye health. Side effects should be reported rather than managed by changing the dose yourself.

Can I stop dexamethasone or prednisone suddenly?

No. Long-term glucocorticoid use can reduce the body's own cortisol production, and stopping suddenly can cause a dangerous adrenal crisis. Ask the prescribing clinician for a safe dose change or tapering plan.

What monitoring is needed with spironolactone, eplerenone, or amiloride?

These medicines can raise potassium and affect kidney function. Clinicians usually check potassium and kidney blood tests before treatment and again during follow-up, with the schedule based on the medicine, dose, and kidney health. Do not start, stop, or substitute one of these medicines without medical instructions.

Does familial hyperaldosteronism type I ever require adrenal surgery?

Usually not, because the genetic change affects both adrenal glands rather than one removable problem. Rarely, a separate adrenal adenoma may cause treatment-resistant disease, and a surgeon may remove one adrenal gland. This decision requires specialist evaluation.

Get notified when new evidence is published on Familial hyperaldosteronism type I.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (18)

1
Inherited Forms of Primary Hyperaldosteronism: New Genes, New Phenotypes and Proposition of A New Classification.
Perez-Rivas LG, Williams TA, Reincke M
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2019; (127(2-03)):93-99 doi:10.1055/a-0713-0629.
PMID: 30199917
2
A Chinese pedigree with glucocorticoid remediable aldosteronism.
Liu X, Jin L, Zhang H, et al.
Hypertension research : official journal of the Japanese Society of Hypertension 2021; (44(11)):1428-1433 doi:10.1038/s41440-021-00685-3.
PMID: 34462604
3
Family hyperaldosteronism type I: a clinical case and review of literature.
Chikladze NM, Favorova OO, Chazova IE
Terapevticheskii arkhiv 2018; (90(9)):115-122 doi:10.26442/terarkh2018909115-122.
PMID: 30701745
4
Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force.
Strehl C, Bijlsma JW, de Wit M, et al.
Annals of the rheumatic diseases 2016; (75(6)):952-7 doi:10.1136/annrheumdis-2015-208916.
PMID: 26933146
5
Secondary Adrenal Insufficiency and Iatrogenic Cushing's Syndrome in a 13-Year-Old Male With Vogt-Koyanagi-Harada Disease: A Case Report.
Paparella R, Bernabei I, Bei A, et al.
Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners 2026; (40(3)):e125-e130 doi:10.1016/j.pedhc.2025.09.013.
PMID: 41128702
6
Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi R, Caratti G, Ray DW, Tomlinson JW
Endocrine reviews 2023; (44(6)):975-1011 doi:10.1210/endrev/bnad016.
PMID: 37253115
7
Extensive expertise in endocrinology: advances in the management of glucocorticoid-induced osteoporosis.
Compston JE
European journal of endocrinology 2023; (188(3)):R46-R55 doi:10.1093/ejendo/lvad029.
PMID: 36880157
8
European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and therapy of glucocorticoid-induced adrenal insufficiency.
Beuschlein F, Else T, Bancos I, et al.
European journal of endocrinology 2024; (190(5)):G25-G51 doi:10.1093/ejendo/lvae029.
PMID: 38714321
9
Glucocorticoid induced adrenal insufficiency.
Prete A, Bancos I
BMJ (Clinical research ed.) 2021; (374()):n1380 doi:10.1136/bmj.n1380.
PMID: 34253540
10
Systematic Review of Therapeutic Agents and Long-Term Outcomes of Familial Hyperaldosteronism Type 1.
Tan ST, Boyle V, Elston MS
Hypertension (Dallas, Tex. : 1979) 2023; (80(7)):1517-1525 doi:10.1161/HYPERTENSIONAHA.123.21054.
PMID: 37170822
11
Glucocorticoid Remediable Aldosteronism in a Family with a Strong History of Cerebral Aneurysms and Hypertension.
Zeman J, Kamilaris C
Prague medical report 2025; (126(3)):151-154 doi:10.14712/23362936.2025.23.
PMID: 40966436
12
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline.
Adler GK, Stowasser M, Correa RR, et al.
The Journal of clinical endocrinology and metabolism 2025; (110(9)):2453-2495 doi:10.1210/clinem/dgaf284.
PMID: 40658480
13
Long-term BP control and vascular health in patients with hyperaldosteronism treated with low-dose, amiloride-based therapy.
Izzo JL, Hong M, Hussain T, Osmond PJ
Journal of clinical hypertension (Greenwich, Conn.) 2019; (21(7)):922-928 doi:10.1111/jch.13567.
PMID: 31169971
14
Maintenance of long-term blood pressure control and vascular health by low-dose amiloride-based therapy in hyperaldosteronism.
Izzo JL, Hong M, Hussain T, Osmond PJ
Journal of clinical hypertension (Greenwich, Conn.) 2019; (21(8)):1183-1190 doi:10.1111/jch.13597.
PMID: 31347775
15
SFE/SFHTA/AFCE consensus on primary aldosteronism, part 4: Subtype diagnosis.
Bardet S, Chamontin B, Douillard C, et al.
Annales d'endocrinologie 2016; (77(3)):208-13.
PMID: 27036860
16
Adrenalectomy Completely Cured Hypertension in Patients With Familial Hyperaldosteronism Type I Who Had Somatic KCNJ5 Mutation.
Lin YF, Peng KY, Chang CH, et al.
The Journal of clinical endocrinology and metabolism 2019; (104(11)):5462-5466 doi:10.1210/jc.2019-00689.
PMID: 31287546
17
Characteristics and Outcomes in Primary Aldosteronism Patients Harboring Glucocorticoid-Remediable Aldosteronism.
Cheng CY, Liao HW, Peng KY, et al.
Biomedicines 2021; (9(12)) doi:10.3390/biomedicines9121816.
PMID: 34944634
18
Familial hyperaldosteronism: an European Reference Network on Rare Endocrine Conditions clinical practice guideline.
Mulatero P, Scholl UI, Fardella CE, et al.
European journal of endocrinology 2024; (190(4)):G1-G14 doi:10.1093/ejendo/lvae041.
PMID: 38571460

This page is for informational purposes only and does not constitute medical advice. Your endocrinology team should tailor FH-I treatment and monitor blood pressure, potassium, kidney function, growth, and steroid effects.